Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

被引：69
|
作者：
Zugmaier, G. [1 ]
Topp, M. S. [2 ,3 ]
Alekar, S. [4 ]
Viardot, A. [5 ]
Horst, H-A [6 ,7 ]
Neumann, S. [6 ,7 ]
Stelljes, M. [8 ]
Bargou, R. C. [3 ]
Goebeler, M. [3 ]
Wessiepe, D. [9 ]
Degenhard, E. [1 ]
Goekbuget, N. [10 ]
Klinger, M. [1 ]
机构：
[1] Amgen Res Munich GmbH, Munich, Germany
[2] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[3] Univ Klinikum Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] Univ Ulm, Dept Med 3, D-89069 Ulm, Germany
[6] City Hosp, Dept Med 2, Kiel, Germany
[7] Univ Hosp Schleswig Holstein, Kiel, Germany
[8] Univ Munster, Bone Marrow Transplantat Ctr, D-48149 Munster, Germany
[9] Metronomia GmbH, Munich, Germany
[10] Goethe Univ Frankfurt, Ctr Internal Med, Frankfurt, Germany
来源：
BLOOD CANCER JOURNAL | 2014年 / 4卷
关键词：
STEM-CELL TRANSPLANTATION; ENGAGING ANTIBODY; FREE SURVIVAL; RITUXIMAB; LYMPHOMA; HYPOGAMMAGLOBULINEMIA; LINEAGE;
D O I：
10.1038/bcj.2014.64
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e244 / e244
页数：4
相关论文
共 50 条
  • [1] Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
    G Zugmaier
    M S Topp
    S Alekar
    A Viardot
    H-A Horst
    S Neumann
    M Stelljes
    R C Bargou
    M Goebeler
    D Wessiepe
    E Degenhard
    N Gökbuget
    M Klinger
    Blood Cancer Journal, 2014, 4 : e244 - e244
  • [2] Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Goekbuget, Nicola
    Dombret, Herve
    Bonifacio, Massimiliano
    Reichle, Albrecht
    Graux, Carlos
    Faul, Christoph
    Diedrich, Helmut
    Topp, Max S.
    Brueggemann, Monika
    Horst, Heinz A.
    Stieglmaier, Julia
    Wessels, Hendrik
    Haddad, Vincent
    Zugmaier, Gerhard
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2015, 126 (23)
  • [3] Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia
    Aboudalle, Iman
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Ravandi, Farhad
    Sasaki, Koji
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    Benton, Christopher B.
    Issa, Ghayas C.
    Khouri, Maria
    Nasnas, Patrice
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2018, 132
  • [4] Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia
    Kathari, Yamini K.
    An, Max
    Dougherty, Christine
    Emadi, Ashkan
    PHARMACEUTICALS, 2024, 17 (03)
  • [5] Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia
    de Haas, V
    Oosten, L
    Dee, R
    Verhagen, OJHM
    Kroes, W
    van den Berg, H
    van der Schoot, CE
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (04) : 1080 - 1086
  • [6] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Dombret, Herve
    Bonifacio, Massimiliano
    Reichle, Albrecht
    Graux, Carlos
    Faul, Christoph
    Diedrich, Helmut
    Topp, Max S.
    Brueggemann, Monika
    Horst, Heinz-August
    Havelange, Violaine
    Stieglmaier, Julia
    Wessels, Hendrik
    Haddad, Vincent
    Benjamin, Jonathan E.
    Zugmaier, Gerhard
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2018, 131 (14) : 1522 - 1531
  • [7] Set up of a new strategy for minimal residual disease monitoring in children with B-precursor acute lymphoblastic leukemia
    Bonjean, B
    Grollet, L
    Visentin, E
    Sigaux, F
    Cayuela, JM
    ANNALES DE BIOLOGIE CLINIQUE, 2004, 62 (04) : 465 - 470
  • [8] Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL)
    Topp, Max S.
    Zugmaier, Gerhard
    Goekbuget, Nicola
    Kufer, Peter
    Goebeler, Mariele
    Klinger, Matthias
    Degenhard, Evelyn
    Baeuerle, Patrick A.
    Schmidt, Margit
    Nagorsen, Dirk
    Neumann, Svenja
    Horst, Heinz A.
    Raff, Thorsten
    Viardot, Andreas
    Stelljes, Matthias
    Schmid, Mathias
    Ottmann, Oliver G.
    Burmeister, Thomas
    Einsele, Hermann
    Riethmueller, Gert
    Hoelzer, Dieter
    Bargou, Ralf C.
    BLOOD, 2009, 114 (22) : 346 - 346
  • [9] The importance of minimal residual disease for detection of late relapse in B-precursor acute lymphoblastic leukemia
    Virijevic, M.
    Kraguljac-Kurtovic, N.
    Pantic, N.
    Knezevic, V
    Mitrovic, M.
    HIPPOKRATIA, 2022, 26 (01) : 38 - 40
  • [10] A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Short, Nicholas J.
    Konopleva, Marina
    Jain, Nitin
    Ravandi, Farhad
    Daver, Naval
    Alvarado, Yesid
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    Velasquez, Michelle
    Garris, Rebecca
    Jabbour, Elias J.
    BLOOD, 2021, 138
12345